Moderate to Severe Binge Eating Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Moderate to Severe Binge Eating Disorder Market Outlook

Thelansis’s “Moderate to Severe Binge Eating Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Binge Eating Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Binge Eating Disorder Overview

Binge Eating Disorder (BED) is defined as an eating disorder marked by repetitive instances of binge eating, during which the person consumes more food than would typically be consumed within a distinct timeframe. Binge eating disorder (BED) is closely related to non-purging bulimia nervosa (BN), although there are distinctions between the two. The key characteristics of BED involve engaging in episodes of binge eating, occurring at least twice a week for six months, and accompanied by considerable distress. Unlike nonpurging bulimia nervosa, BED does not involve compensatory actions to avoid weight gain, such as self-induced vomiting, laxative or diuretic use, or other medications. While many individuals with BED are overweight, not all fall into this category. Overweight individuals with BED are subject to the typical health risks of obesity, such as diabetes, hypertension, and orthopedic issues. The binge-eating disorder commonly emerges as an outcome or consequence of depression. Individuals often resort to “comfort foods” to cope with their depressive feelings. The development of binge-eating disorder, similar to anorexia nervosa or bulimia nervosa, may initiate from low self-esteem or self-image. This disorder tends to arise when attempts to enhance self-assurance prove unsuccessful or go unrecognized externally. Faulty internal communication can also contribute to the development of binge-eating disorder. Factors that contribute to the emergence of this disorder include severe childhood obesity, a family history of overeating, experiences of body-related bullying or teasing, and substance abuse such as drugs or alcohol. Binge-eating disorder is most frequently identified in individuals who are overweight or obese. Current diagnostic criteria necessitate the occurrence of at least one binge episode per week for a duration of three months. Individuals grappling with binge-eating disorder are at an elevated risk of encountering depression and substance misuse. The treatment of binge-eating disorder in adults has succeeded through a combination of cognitive-behavioral therapy and antidepressant medication. BED is the most prevalent eating disorder in both the United States and Europe, with higher occurrences observed among teenagers and young adults. On average, the onset of BED occurs around the age of 25.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Moderate to Severe Binge Eating Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034